Cubist Systematic Strategies’s Day One Biopharmaceuticals DAWN Stock Holding History

Cubist Systematic Strategies’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-193,857	Closed	-$1.26M	–	3108
2025 Q2	$1.26M	Buy	+193,857	New	+$1.33M	0.01%	1819
2024 Q4	–	Sell	-68,064	Closed	-$948K	–	3083
2024 Q3	$948K	Buy	+68,064	New	+$971K	0.01%	1866
2024 Q1	–	Sell	-14,395	Closed	-$210K	–	3835
2023 Q4	$210K	Buy	+14,395	New	+$175K	﹤0.01%	2979
2023 Q2	–	Sell	-172,408	Closed	-$2.31M	–	3658
2023 Q1	$2.31M	Buy	172,408 +128,850	+296%	+$2.52M	0.01%	1564
2022 Q4	$937K	Sell	43,558 -82,028	-65%	-$1.68M	0.01%	2506
2022 Q3	$2.52M	Buy	125,586 +64,349	+105%	+$1.37M	0.01%	1768
2022 Q2	$1.1M	Buy	+61,237	New	+$632K	0.01%	2412

Other funds holding DAWN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Cubist Systematic Strategies's DAWN Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Day One Biopharmaceuticals (DAWN) in Q3 2025, closing a stake of 193,857 shares — an estimated $1.26M sold.

Cubist Systematic Strategies first reported a position in DAWN in Q2 2022 and held it in 7 quarters. The position peaked at $2.52M in Q3 2022. 172 funds tracked by Wall St. Rank hold DAWN as of Q3 2025.

Cubist Systematic Strategies reported no remaining Day One Biopharmaceuticals position as of Q3 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 193,857 Day One Biopharmaceuticals shares in Q3 2025, an estimated $1.26M.
Cubist Systematic Strategies first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 7 quarters.
Cubist Systematic Strategies's Day One Biopharmaceuticals position peaked at $2.52M in Q3 2022.
172 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.